🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Iparomlimab and Tuvonralimab

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) NCT07165847Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur, Radiotherapy Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence NCT06954116Phase 21 site📍 Wuhan Tongji Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT NCT07327788Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Iparomlimab and Tuvonralimab Injection (QL1706), Bevacizumab, Hepatic Arterial Infusion Chemotherapy with Raltitrexed a… Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer NCT07315854Phase 21 site📍 Beijing Beijing Friendship Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer NCT07082179Phase 21 site📍 Nanjing Jiangsu Cancer Institute & Hospital · Tests: Iparomlimab and Tuvonralimab combined with paclitaxel polymer micelles and Platinum (cisplatin/carboplatin) Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer NCT07267078Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Tuvonralimab/Iparomlimab combination with GEMOX chemotherapy Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction Cancer NCT07867392Phase 21 site📍 Shanghai Ruijin Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), nab-P-SOX（nab-paclitaxel, oxaliplatin, S-1） Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07876154Phase 21 site📍 Xi'an Xijing Hospital · Tests: Iparomlimab/Tuvonralimab, nab-paclitaxel, Cisplatin, Carboplatin (AUC 5) Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer NCT07127822Phase 210 sites📍 Shijiazhuang📍 Harbin📍 Zhengzhou Peking University · Tests: Iparomlimab and Tuvonralimab, First line chemotherapy plus PD-1/PD-L1 antibody Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer NCT07686640Phase 31 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Short-Course Radiotherapy, Consolidation treatment (With ICIs), Consolidation treatment (Without ICIs) Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) NCT07289997Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Iparomlimab and Tuvonralimab Injection (QL1706) Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer NCT07180160Phase 21 site📍 Shanghai Wenjin Yin · Tests: QL1706, CDK4/6 inhibitor, Fulvestrant Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07646301Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin, Carboplatin Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial NCT07847359Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine, Lenvatinib Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus NCT07776080Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy, hepatic arterial infusion chemotherapy (HAIC) Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC NCT06878222Phase 21 site📍 Shanghai Obstetrics & Gynecology Hospital of Fudan University · Tests: Neoadjuvant Chemotherapy, Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery, Fertility-preserving surgery Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC NCT07801287Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Iparomlimab/Tuvonralimab plus SBRT and Lenvatinib Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma NCT07099274Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial NCT07101744Phase 21 site📍 Guangdong Sun Yat-sen University · Tests: Iparomlimab and Tuvonralimab Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer NCT06942416Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Paclitaxel and Cisplatin/ Carboplatin, Iparomlimab and Tuvonralimab, Radiotherapy QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer NCT07110064Phase 21 site📍 Nanjing Du Juan · Tests: QL1706+Lenvatinib+AG Regimen SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer NCT06864013Phase 21 site📍 Hangzhou First Affiliated Hospital of Zhejiang University · Tests: Experimental, Control Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma NCT07070700Phase 21 site📍 Shanghai Fudan University · Tests: QL1706 (bispecific antibody targeting PD-1 and CLTA-4), Lenvatinib, cryoablation A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined With SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma NCT06829797Phase 21 site📍 Jinan Shandong Provincial Hospital · Tests: Neoadjuvant Therapy(QL1706+SOX Chemotherapy), Neoadjuvant Therapy(SOX Chemotherapy), Radical surgery (D2), Drug: Adjuva… The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma NCT07290010Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Iparomlimab and Tuvonralimab combined with chemotherapy Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma NCT07014150Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Lenvatinib, Iparomlimab and Tuvonralimab Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy NCT07372079Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: QL1706 combined with Chemotherapy A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT07546383NA1 site📍 Haikou The Second Affiliated Hospital of Hainan Medical University · Tests: Iparomlimab and tuvonralimab Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC NCT07232654Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Iparomlimab/Tuvonralimab, Cisplatin, Brachytherapy and External Beam Radiotherapy Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC NCT07882888Phase 21 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: iparomlimab and tuvonralimab combined with cetuximab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy